


Technology Advisory Committee A Interests Register

Topic: Olaparib for adjuvant treatment of high-risk HER2-negative, BRCA-positive early breast cancer after

chemotherapy [ID3893] Publication Date: 10/05/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Hugo Pedder	Committee Member	non-financial professional & personal interests	He is a member of Bristol TAG with whom he has worked on this appraisal.		26/09/22		As a direct conflict Hugo did not participate in discussions on this appraisal.
Holly Heath	Patient expert	indirect financial interests	In the last 12 months Breast Cancer Now has received funding from the manufacturer AstraZeneca towards the Helpline. Breast Cancer Now funded researchers are involved in PARP inhibitor research. Breast Cancer Now receives from The Institute of Cancer Research (ICR) a share of royalties/payments from sales of olaparib by AstraZeneca and Merck.		28/02/22		It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
Melanie Sturtevant	Patient expert	indirect financial interests	In the last 12 months Breast Cancer Now has received funding from the manufacturer AstraZeneca towards the Helpline. Breast Cancer Now funded		28/02/22		It was agreed that her declaration would not prevent Melanie from providing expert advice to the committee.



			researchers are involved in PARP inhibitor research. Breast Cancer Now receives from The Institute of Cancer Research (ICR) a share of royalties/payments from sales of olaparib by AstraZeneca and Merck.		
Professor Andrew Tutt	Clinical expert	direct financial interests	He has received personal fees from several pharmaceutical companies, including AstraZeneca, and receives a share of royalties from ICR relating to sales of olaparib and other PARP inhibitors. He also declared indirect interests as there have been payments to his academic and hospital institutions for research and speaking, including from AstraZeneca.	03/03/22	It was agreed his declarations would not prevent Professor Tutt from providing expert advice to the committee.